The assessment of cognitive decline when accompanied by Aβ and tau discordance, or alternatively, of the individuals that may be overlooked if prioritizing tau over Aβ biomarkers, is a pivotal step before the clinical establishment of tau biomarkers. The gene discussed is MAPT; the disease is Mental deterioration.